Friends of Cancer Research Annual Meeting 2023
Thank you to everyone who was able to join!
Please click through below to access the meeting recording as well as the panel white papers.
Watch the Friends Annual Meeting 2023
Panel 1 — Early Phase Trials: Data Implementation and Interpretation for Dose-Finding
White Paper – Topic Primer
Panel 2 — Incorporating Pragmatic Trial Elements into Oncology Drug Development
White Paper – Topic Primer
Panel 3 — Maximizing Use of Data from Academic-Led Studies for Regulatory Decision-Making
White Paper – Topic Primer
Tuesday, November 14, 202310:00AM – 3:00PM ETThe Ritz Carlton
1150 22nd St NW, Washington, DC 20037
Conference will also be streamed virtually
Friends of Cancer Research (Friends) is proud to host our 16th Annual Meeting to address critical issues in the development of new oncology drugs. Each Friends Annual Meeting brings together leaders from federal health and regulatory agencies, academic research, the private sector, and patient advocates to propose unique approaches toward current challenges in drug development.
Click the button above to register.
Agenda
9:30 AM: Meeting Registration
10:00 AM: Welcome
- Ellen Sigal, Friends of Cancer Research
10:02 AM: Morning Keynote Conversation
- Jeff Allen, Friends of Cancer Research — Moderator
- Monica Bertagnolli, NIH
- Robert Califf, U.S. FDA
10:30 AM: Panel 1 Discussion – Early Phase Trials: Data Implementation and Interpretation for Dose-Finding
Click here to learn more about Panel 1
Click here to read the White Paper
- Julie Bullock, Certara — Moderator
- Judith Fitzgerald, Patient Advocate
- Ramon Kemp, GSK
- Enrique Sanz Garcia, Princess Margaret Cancer Centre
- Mirat Shah, U.S. FDA
- Gita Thanarajasingam, Mayo Clinic
11:30 AM: Break
11:45 AM: Panel 2 Discussion – Incorporating Pragmatic Trial Elements into Oncology Drug Development
Click here to learn more about Panel 2
Click here to read the White Paper
- Nafsika Kronidou Horst, F. Hoffmann-La Roche — Moderator
- Erin Larkins, U.S. FDA
- Boris Kin Lin, Eli Lilly and Company
- Sumithra Mandrekar, Mayo Clinic/The Alliance for Clinical Trials in Oncology
- Kristin McJunkins, Patient Advocate
- Margaret Mooney, NCI Cancer Therapy Evaluation Program
12:45 PM: Lunch
1:15 PM: Lunch Keynote — Overview of OCE Projects
- Richard Pazdur, U.S. FDA OCE — Moderator
- Rea Blakey, U.S. FDA OCE — Project Community
- Mitchell Chan, U.S. FDA OCE — Project Facilitate
- R. Angelo de Claro, U.S. FDA OCE — Project ORBIS
- Gautam Mehta, U.S. FDA OCE — Project Confirm
- Jeff Summers, U.S. FDA OCE — Project Catalyst
1:55 PM: Panel 3 Discussion – Maximizing Use of Data from Academic-Led Studies for Regulatory Decision-Making
Click here to learn more about Panel 3
Click here to read the White Paper
- Kathleen Winson, Genentech — Moderator
- Kristina Laumann, Mayo Clinic
- Margaret Mooney, NCI Cancer Therapy Evaluation Program
- Christy Osgood, U.S. FDA
- Russ Palmer, EMD Serono
- Sunita Zalani, Merck & Co., Inc.
2:55 PM: Closing Remarks
3:00 PM: Meeting Adjournment
